L26/O-196 From atypical fertilization to last-chance success: the real clinical value of 1PN-embryos in IVF
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Ahlstrom und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Which is the contribution of 1PN-derived embryos to the cumulative live birth rate per oocyte retrieval (cLBR) in IVF? Summary answer The use of 1PN-derived embryos as last chance involves ≥3% and ≥19% relative-increase in cLBR among cycles with ≥1PN-zygote and ≥1 1PN-derived embryo, respectively. What is known already 1PN-zygotes display reduced developmental competence compared with 2PN-zygotes, but when reaching the blastocyst stage show comparable clinical outcome. In fact, cumulative evidence, including over 1000 transfers worldwide, suggests reassuring implantation and obstetric outcomes with no increase in adverse events. On this basis, ESHRE and Alpha, in the updated Istanbul consensus, support a cautious clinical use of 1PN zygotes, ideally combined with blastocyst culture and PGT-A for biparental diploidy assessment. Nevertheless, most data derive from single-center studies, and true 1PN status is often not confirmed through time-lapse imaging. Study design, size, duration Retrospective observational multi-center study at 8 private IVF clinics in Sweden and Iceland between 2016 and 2024. All 46886 cycles included by 15600 couples (mean age:35.4yr, mean BMI:24.6Kg/m2; 19% characterized by severe-male-factor) underwent time-lapse culture. 1PN-zygotes were systematically cultured and, if developing into viable embryos, they were transferred as last-chance option. We assessed the relative contribution of 1PN-derived embryos to the cLBR overall, per cycle with ≥1 1PN-zygote and with ≥1 1PN-derived viable embryo. Participants/materials, setting, methods All oocytes retrieved were inseminated by IVF and/or ICSI and cultured in time-lapse-incubators. Only untested single embryo-transfers were performed. First transfers, if fresh, were either at the cleavage- or blastocyst-stage (≥3BB). Only blastocysts (≥3BB) were vitrified. Multivariable mixed-effects logistic-regressions tested associations with live-birth in 1PN-embryos vs 2PN-embryos unmatched and matched per confounders. The relative-contribution of 1PN-embryos to cLBR was calculated as additional cycles with ≥1 LB divided by cycles that achieved ≥1 LB with 2PN-embryos. Main results and the role of chance Overall, 448049 cumulus-oocyte-complexes were retrieved (mean:10.2 in 46886 cycles). The 218876 2PN-zygotes obtained (mean:5) resulted into 94482 useable 2PN-embryos (mean:2.2; 43.2% blastulation-rate) in 35054 cycles, while 13412 1PN-zygotes (mean:0.3) resulted into 1355 useable 1PN-embryos (mean:0.03 overall and 0.13 among cycles with ≥1 1PN-zygote cultured; 10.1% blastulation-rate, p < 0.001) in 1258 cycles. Overall, 46409 2PN-embryos were transferred in 28568 cycles and resulted into 15709 live-births (33.3%) in 13726 cycles, while 477 1PN-embryos were transferred in 467 cycles and resulted into 143 live-births (30%) in 143 cycles. From the whole dataset, 2PN-embryos showed higher LB-rate per transfer than 1PN-embryos (aOR:1.27, 95%CI:1.03-1.56, p = 0.027; adjusted for age, IVF-center, day of transfer, embryo quality). When matching the groups with a propensity score matching approach, the LB-rate was comparable between 2PN- and 1PN-embryos (aOR:1.06, 95%CI:0.78-1.44, p = 0.719). In 111 cycles the only live-birth was achieved thanks to 1PN-embryos that add-up to the 4118 cycles with ≥1 1PN-zygote where 2PN-embryos resulted into a live-birth (cLBR relative-increase:+3%) or to the 581 cycles with ≥1PN-embryo where 2PN-embryos resulted into a live-birth (cLBR relative-increase:+19%). These rates were +2% and +14% in women <35yr, +3% and +20% at 35-37yr, +4% and +12% at 38-39yr, +5% and 14% at 40-41 yr, +3% and 23% at ≥ 42yr. Limitations, reasons for caution Retrospective analysis. PGT-A was not conducted as prohibited in Sweden. 1PN-embryos might contribute also to second children. 1PN contribution might be higher than reported here as many cycles with or without 2PN-blastocysts still have 1PN-blastocysts available for transfer. Wider implications of the findings The strengths of this study are an unprecedented sample size, systematic time-lapse confirmation of 1PN-status and culture, and single-embryo transfer policy. These findings support a clinically-meaningful role of 1PN-embryos as last-chance option in poor-prognosis patients. The decision-making should be deferred to the blastocyst stage, especially if euploidy can be assessed. Trial registration number No
Zitieren
APA
Ahlstrom, A., Esfangani, A. K., Gudmunsén, J., Coticchio, G., Kalafat, E., Ottolini, C., Capalbo, A., Rienzi, L., & Cimadomo, D. (2026). L26/O-196 From atypical fertilization to last-chance success: the real clinical value of 1PN-embryos in IVF. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.194
Vancouver
Ahlstrom A, Esfangani AK, Gudmunsén J, Coticchio G, Kalafat E, Ottolini C, et al. L26/O-196 From atypical fertilization to last-chance success: the real clinical value of 1PN-embryos in IVF. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.194
BibTeX
@article{Ahlstrom2026,
author = {Ahlstrom, A. and Esfangani, A. Khatibi and Gudmunsén, J. and Coticchio, G. and Kalafat, E. and Ottolini, C.S. and Capalbo, A. and Rienzi, L. and Cimadomo, D.},
title = {L26/O-196 From atypical fertilization to last-chance success: the real clinical value of 1PN-embryos in IVF},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.194}
}
EUVIMED